Spots Global Cancer Trial Database for A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Official Title: A Post Marketing Surveillance Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Study ID: NCT05375136

Conditions

Endometrial Neoplasms

Endometrium

Carcinoma

Renal Cell Carcinoma

Interventions

Non-interventional

Study Description

Brief Summary: The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Lenvatinib in lenvatinib/pembrolizumab combination therapy in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the approved product package insert of lenvatinib in lenvatinib/pembrolizumab combination therapy (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.

Detailed Description: